TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A physician’s report argues that people who notice persistent changes in memory or thinking may merit a fuller evaluation even when cognitive tests fall in the normal range. Subjective cognitive decline is not a diagnosis of Alzheimer’s, and the article says symptoms can have many causes; it describes repeat testing and, for selected patients, biomarkers as possible parts of assessment.
Subjective cognitive decline (SCD) refers to a person’s ongoing sense that their cognitive abilities have worsened compared with their previous level, despite testing that does not find objective impairment. Chin, a memory-care physician at UW Health and University of Wisconsin–Madison associate professor, says a normal score can miss a meaningful change from an individual’s past abilities. Standard comparisons often use people of similar age rather than a person’s own earlier performance.
Chin distinguishes a brief screening test, which he says typically takes five to 15 minutes, from a comprehensive evaluation that may take an hour or longer and assess memory, language, attention and executive function. He argues that a thorough baseline and repeated testing over time can help establish whether a person remains stable or is declining, even if scores have not crossed into an impaired range.
The article also describes “SCD plus,” a set of features developed by psychiatrist Frank Jessen and colleagues in the international Subjective Cognitive Decline Initiative. These include memory-focused concerns, onset in the past five years, onset at age 60 or older, worry, persistence, seeking medical help and another person confirming the change. Chin says these features do not prove Alzheimer’s, but several occurring together may justify closer attention. He also names sleep problems, medication effects, depression or anxiety, illness, vascular disease, hearing loss, stress and normal aging as possible contributors.
Why Normal Scores May Miss Change
The report challenges a simple interpretation of normal testing: that a person’s concerns can be set aside until a score becomes impaired. Testing against age peers may not reveal a decline from someone’s own higher starting point, Chin says. That distinction can matter for patients and clinicians deciding whether to document a baseline, investigate other explanations or arrange follow-up.
The potential relevance to Alzheimer’s is an earlier opportunity for assessment, not a promise of prevention or treatment. Chin says selected patients may also consider tests for Alzheimer’s-related biological changes. The article does not establish that everyone with SCD should receive biomarkers or that early testing changes outcomes. Its practical message is to evaluate persistent concerns rather than treating a normal screening score as the whole picture.
Popular right now
Ninja Foodi 10-Quart DualZone 6-in-1 Air Fryer, Black, DZ302
Samsung 42-Inch S90H OLED 4K Smart TV Bundle
Bose QuietComfort Wireless Noise-Cancelling Over-Ear Headphones, Black
As an affiliate, we earn on qualifying purchases.
How SCD Differs From Impairment
SCD describes a reported change without measurable impairment on comprehensive cognitive testing; it is not a disease diagnosis or an explanation for symptoms. Chin notes that brief screens sample a limited range of abilities, while a fuller evaluation examines several cognitive domains. Determining whether SCD is present therefore requires enough assessment to judge whether objective impairment has already emerged.
The article uses two contrasting examples: a person with intermittent word-finding worries over many years, often amid poor sleep or stress, and a person over 60 with a more recent, persistent memory change that worries both the individual and a spouse. Both might test within normal limits, but Chin says their histories would not prompt the same clinical response. The comparison illustrates why onset, persistence and corroboration matter, while not diagnosing either person.
What SCD Cannot Establish
The report does not say how often people with SCD go on to develop Alzheimer’s, nor does it provide a risk estimate for people with particular SCD-plus features. Those features are described as reasons for greater concern, not proof of disease. The source excerpt also does not provide study results establishing how much earlier evaluation or biomarker testing changes a patient’s outcome.
Chin raises blood biomarkers, cerebrospinal fluid testing and amyloid PET as ways to ask whether Alzheimer’s-related biological changes are present in selected patients. The available material ends before giving details about who should be tested, test performance, access, risks or how results should guide care. It is also unclear from the article how clinicians should choose among these tests in individual cases. A clinician’s evaluation remains necessary because SCD can have multiple causes.
Baseline Testing and Follow-Up
Chin’s proposed next steps are to take persistent concerns seriously, conduct a comprehensive cognitive evaluation, consider observations from someone familiar with the person’s abilities, check for other possible contributors and repeat testing over time. For selected patients, he says clinicians may also consider Alzheimer’s biomarkers. The article does not announce a new guideline or prescribe a universal testing pathway.
For readers, the immediate development is the publication of a physician’s perspective, not a change in diagnostic criteria. The next clinical question is whether an individual’s symptoms, history and test results warrant further assessment. Anyone concerned about a change in memory or thinking can discuss it with a qualified health professional; this report is not a diagnosis or personal medical advice.
Key Questions
What is subjective cognitive decline?
SCD is a persistent feeling that memory or other cognitive abilities have declined from a person’s previous level, even though comprehensive testing does not show objective impairment. It describes a reported change, not its cause.
Does subjective cognitive decline mean someone has Alzheimer’s?
No. Chin says SCD alone does not establish Alzheimer’s. Sleep, medications, mood, illness, vascular disease, hearing loss, stress and normal aging can also affect how sharp someone feels.
What does “SCD plus” mean?
It refers to features that may make subjective decline more concerning, such as recent memory-focused change, persistence, worry, onset at age 60 or older, seeking medical help and confirmation by someone who knows the person. These features do not prove Alzheimer’s.
Why might a normal cognitive test not settle the question?
A brief screen covers only part of cognition, and scores may compare a person with age peers rather than with their own earlier abilities. Chin says a fuller evaluation and repeat testing can help track change over time.
Can biomarkers detect Alzheimer’s before cognitive impairment?
Chin says blood tests, cerebrospinal fluid testing and amyloid PET can help assess Alzheimer’s-related biological changes in selected patients. The source does not set out who should receive these tests or show that testing guarantees a particular outcome.
Source: beingpatient.com
